Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation

References

• Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19:324–35.
   PubMed Web of Science ®Google Scholar
• Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009;44:457–62.
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115:3861–8.
   PubMed Web of Science ®Google Scholar
• Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E, . Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2006;12:919–27.
   PubMed Web of Science ®Google Scholar
• Hoegh-Petersen M, Sy S, Ugarte-Torres A, Williamson TS, Eliasziw M, Mansoor A, . High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation. Leukemia. 2012;26:359–62.
   PubMedGoogle Scholar
• Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, . Impaired recovery of Epstein–Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101: 4290–7.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, . Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904.
   PubMed Web of Science ®Google Scholar
• Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, . Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol. 1994;12:2187–92.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, . Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–5.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J, . Pre-emptive treatment of acute GVHD: a randomized multileft trial of rabbit anti- thymocyte globulin, given on day  7 after alternative donor transplants. Bone Marrow Transplant. 2010;45:385–91.
   PubMed Web of Science ®Google Scholar
• Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant. 2009;15:996–9.
   PubMed Web of Science ®Google Scholar
• Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant. 2010;16:915–26.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–94.
   PubMed Web of Science ®Google Scholar
• Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, . Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79:1507–15.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Flacher M, Revillard JP. Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood. 1992;79:2164–70.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435–42.
   PubMed Web of Science ®Google Scholar
• LaCorcia G, Swistak M, Lawendowski C, Duan S, Weeden T, Nahill S, . Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation. 2009;87:966–74.
   PubMed Web of Science ®Google Scholar
• Eiermann TH, Lambrecht P, Zander AR. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant. 1999;23:779–81.
   PubMedGoogle Scholar
• Haidinger M, Geyeregger R, Poglitsch M, Weichhart T, Zeyda M, Vodenik B, . Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation. 2007;84:117–21.
   PubMedGoogle Scholar
• Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, . Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation. 2003;75: 2135–43.
   PubMedGoogle Scholar
• Fehse N, Fehse B, Kroger N, Zabelina T, Freiberger P, Kruger W, . Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res. 2003;12:237–42.
   PubMedGoogle Scholar
• Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, . Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant. 1997;3:65–75.
   PubMedGoogle Scholar
• Behringer D, Bertz H, Schmoor C, Berger C, Dwenger A, Finke J. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34  selected PBPC grafts, unselected PBPC grafts or BM grafts. Bone Marrow Transplant. 1999;24:295–302.
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, . Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97:3380–9.
   PubMed Web of Science ®Google Scholar
• Fallen PR, McGreavey L, Madrigal JA, Potter M, Ethell M, Prentice HG, . Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant. 2003;32:1001–14.
   PubMed Web of Science ®Google Scholar
• Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, . Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest. 2005;115:930–9.
   PubMed Web of Science ®Google Scholar
• Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood. 1998;91:3481–6.
   PubMed Web of Science ®Google Scholar
• Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, . Donor serostatus impacts cytomegalovirus-specific immunity, cytomegaloviral disease incidence and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;4:574–85.
   PubMedGoogle Scholar
• Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, . Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–7.
   PubMed Web of Science ®Google Scholar
• Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, . Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93:467–80.
   PubMed Web of Science ®Google Scholar
• Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson EM, . Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood. 1978;51:1087–105.
   Google Scholar
• Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34  -selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11: 609–18.
   PubMedGoogle Scholar
• Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45:29–32.
   PubMed Web of Science ®Google Scholar
• Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25  Foxp3  regulatory T cells. J Am Soc Nephrol. 2006;17:2844–53.
   PubMed Web of Science ®Google Scholar
• Federmann B, Hagele M, Pfeiffer M, Wirths S, Schumm M, Faul C, . Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia. 2011;25:121–9.
   PubMed Web of Science ®Google Scholar
• Martinez C, Urbano-Ispizua A, Rozman C, Marin P, Rovira M, Sierra J, . Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34  selected grafts with recipients of unmanipulated grafts. Exp Hematol. 1999;27: 561–8.
   PubMed Web of Science ®Google Scholar
• Theilgaard-Monch K, Raaschou-Jensen K, Palm H, Schjodt K, Heilmann C, Vindelov L, . Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 2001;28:1073–82.
   PubMed Web of Science ®Google Scholar
• Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, . Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5:465–74.
   PubMed Web of Science ®Google Scholar
• Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005;205:72–93.
   PubMed Web of Science ®Google Scholar
• Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, . Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96:298–306.
   PubMed Web of Science ®Google Scholar
• Rouse T, Ahmed R. Immune response to viruses. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HWJ, (eds.). Clinical Immunology. London: Mosby, 2001;pp. 28:10–28.21.
   Google Scholar
• Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood. 2001;98:489–91.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia J, Serrano J, Gomez P, Martinez F, Martin C, Roman-Gomez J, . The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica. 2006;91:340–7.
   PubMedGoogle Scholar
• Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol. 1996;52:82–9.
   PubMedGoogle Scholar
• Schreiber KL, Forman J. The effect of chronic graft-versus-host disease on B cell development. Transplantation. 1993;55:597–604.
   PubMedGoogle Scholar
• Huang Y, Parker M, Xia C, Peng R, Wasserfall C, Clarke T, . Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol. 2009;182:4608–15.
   PubMedGoogle Scholar
• Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 1995;16:413–25.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Theorin N, Karlsson K, Frodin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplantation. 2006;37:503–10.
   PubMed Web of Science ®Google Scholar
• Glotzbecker B, Mills H, Rosenblatt J, Wu Z, Wellenstein K, Vasir B, . A comparative analysis of immune reconstitution following reduced intensity conditioning with CAMPATH-1H and total lymphoid irradiation/anti- thymocyte globulin prior to allogeneic stem cell transplantation. American Society of Hematology (ASH) Annual Meeting 2009 in New Orleans, Abstract .
   Google Scholar
• Talukdar AJ, Ashokkumar C, Wilson P, Gupta A, Sun Q, Boig L, . Lymphocyte subset reconstitution patterns in children with small bowel transplantation induced with steroid-free rabbit anti-human thymocyte globulin. Ped Transplant. 2009;13:353–9.
   PubMedGoogle Scholar
• Koller U, Hinterberger W, Gschwandtler L, Grumayer R, Majdic O, Knapp W. Identification of activated T cells and the suppressor/inducer subset in patients suffering from severe aplastic anemia. Blut. 1989;58:21–6.
   PubMedGoogle Scholar
• Terasako K, Sato K, Sato M, Kimura S, Nakasone H, Okuda S, . The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. 2010;15:165–9.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430–8.
   PubMed Web of Science ®Google Scholar
• Jamieson AM, Isnard P, Dorfman JR, Coles MC, Raulet DH. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol. 2004;172:864–70.
   PubMed Web of Science ®Google Scholar
• Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med. 2011;208:357–68.
   PubMed Web of Science ®Google Scholar
• Timm MM, Kimlinger TK, Haug JL, Kline MP, Greipp PR, Rajkumar SV, . Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia. 2006;20:1863–9.
   PubMedGoogle Scholar
• Schroeder HWJ. Clinical Immunology. London: Mosby, 2001.
   Google Scholar
• Miller JJ, Cole LJ. The radiation resistance of long-lived lymphocytes and plasma cells in mouse and rat lymph nodes. J Immunol. 1967;98:982–90.
   PubMedGoogle Scholar
• Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 1998; 8:363–72.
   PubMed Web of Science ®Google Scholar
• Ruzek MC, Neff KS, Luong M, Smith KA, Culm-Merdek K, Richards SM, . In vivo characterization of rabbit anti-mouse thymocyte globulin: a surrogate for rabbit anti-human thymocyte globulin. Transplantation. 2009;88:170–9.
   PubMedGoogle Scholar
• Heitger A, Neu N, Kern H, Panzer-Grumayer ER, Greinix H, Nachbaur D, . Essential role of the thymus to reconstitute naive (CD45RA+  T-helper cells after human allogeneic bone marrow transplantation. Blood. 1997;90:850–7.
   PubMed Web of Science ®Google Scholar
• Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117:6768–76.
   PubMedGoogle Scholar
• Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, . Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:921–3.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Pillai AB, Lowsky R, Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol. 2010;40:1862–9.
   PubMed Web of Science ®Google Scholar
• Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol. 2011;140:184–95.
   PubMedGoogle Scholar